Human Mena+11a isoform serves as a marker of epithelial phenotype and sensitivity to epidermal growth factor receptor inhibition in human pancreatic cancer cell lines

Clinical Cancer Research

Volumn 14, Issue 15, 2008, Pages 4943-

  Pino, Maria S ^a   Balsamo, Michele ^a,d   Modugno, Francesca Di ^a   Mottolese, Marcella ^a   Alessio, Massimo ^b   Melucci, Elisa ^a   Milella, Michele ^a   McConkey, David J ^c   Philippar, Ulrike ^d   Gertler, Frank B ^d   Natali, Pier Giorgio ^a   Nisticò, Paola ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c UNIVERSITY OF TEXAS   (United States)

^d MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MENA 11A PROTEIN; MENA PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; RECOMBINANT EPIDERMAL GROWTH FACTOR; UNCLASSIFIED DRUG; VASODILATOR STIMULATED PHOSPHOPROTEIN; ACTIN BINDING PROTEIN; ENAH PROTEIN, HUMAN; QUINAZOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; PANCREAS ADENOCARCINOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ADENOCARCINOMA; CHEMISTRY; DRUG ANTAGONISM; EPITHELIUM; MESODERM; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; PHYSIOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ADULT; AGED; CELL LINE, TUMOR; CELL PROLIFERATION; EPITHELIUM; HUMANS; MESODERM; MICROFILAMENT PROTEINS; MIDDLE AGED; PANCREATIC NEOPLASMS; PHENOTYPE; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 51049084629     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0436     Document Type: Article

References (50)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer Statistics, 2007. CA Cancer J Clin 2007;57: 43-66.
2. Burris H Ill, Moore M, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as firstline therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997;15:2403-13.
3. Heinemann V, Quietzsch D, Gieseler F, et al. Randomized phase iii trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 2006;24:3946-52.
4. Louvet C, Labianca R, Hammel P, et al. Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 2005;23:3509-16.
5. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1960-6.
6. Oettle H, Richards D, Ramanathan RK, et al. A phase III trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 2005;16:1639-45.
7. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response Rate. J Clin Oncol 2004;22:3776-83.
8. Van Cutsem E, van deVelde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004;22:1430-8.
9. Bria E, Milella M, Gelibter A, et al. Gemcitabine-based combinations for inoperable pancreatic cancer: Have we made real progress? Cancer 2007;110:525-33.
10. Grandis J, Melhem M, Gooding W, et al. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-32.
11. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232.
12. Kondapaka SB, Fridman R, Reddy KB. Epidermal growth factor and amphiregulin up-regulate matrix metalloproteinase-9 (MMP-9) in human breast cancer cells. Int J Cancer 1997;70:722-6.
13. Ennis BW, Lippman ME. Dickson RB. The EGF receptor system as a target for antitumor therapy. Cancer Invest 1991;9:553-62.
14. Olayioye MA, Neve RM, Lane HA, Hynes NE. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 2000;19: 3159-67.
15. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001;2: 127-37.
16. Yamanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993;13:565-9.
17. Barton CM, Hall PA, Hughes CM, Gullick WJ, Lemoine NR. Transforming growth factor a and epidermal growth factor in human pancreatic cancer. J Pathol 1991;163:111-6.
18. Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor α. J Clin Invest 1992;90:1352-60.
19. Wagner M, Cao T, Lopez ME, et al. Expression of a truncated EGF receptor is associated with inhibition of pancreatic cancer cell growth and enhanced sensitivity to cisplatinum. Int J Cancer 1996;68:782-7.
20. Moasser MM, Basso A, Averbuch SD, Rosen N. The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells. Cancer Res 2001; 61:7184-8.
21. Engelman JA, Janne PA, Mermel C, et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci U S A 2005;102:3788-93.
22. Thomson S, Buck E, Petti F, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005;65:9455-62.
23. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39.
24. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
25. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005;353:133-44.
26. Yamaguchi H, Wyckoff J, Condeelis J. Cell migration in tumors. Curr Opin Cell Biol 2005;17:559-64.
27. Karnoub AE, Dash AB, Vo AP, et al. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 2007;449:557-63.
28. Hay ED. The mesenchymal cell, its role in the embryo, and the remarkable signaling mechanisms that create it. Dev Dyn 2005;233:706-20.
29. Lee JM, Dedhar S, Kalluri R. Thompson EW. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006; 172:973-81.
30. Buck E, Eyzaguirre A, Barr S, et al. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther 2007;6: 532-41.
31. Black PC, Brown GA, Inamoto T, et al. Sensitivity to epidermal growth factor receptor inhibitor requires E- cadherin expression in urothelial carcinoma cells. Clin Cancer Res 2008;14:1478-86.
32. Shrader M, Pino MS, Brown G, et al. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther 2007;6:277-85.
33. Krause M, Dent EW, Bear JE, Loureiro JJ, Gertler FB. Ena/VASP proteins: regulators of the actin cytoskeleton and cell migration. Annu Rev Cell Dev Biol 2003; 19:541-64.
34. Di Modugno F, Mottolese M, Di Benedetto A, et al. The cytoskeleton regulatory protein hMena (ENAH) is overexpressed in human benign breast lesions with high risk of transformation and human epidermal growth factor receptor-2-positive/hormonal receptor-negative tumors. Clin Cancer Res 2006;12: 1470-8.
35. Di Modugno F, Bronzi G, Scanlan MJ, et al. Human Mena protein, a serex-defined antigen overexpressed in breast cancer eliciting both humoral and CD8+ T-cell immune response. Int J Cancer 2004;109: 909-18.
36. Di Modugno F, DeMonte L, Balsamo M, et al. Molecular cloning of hMena (ENAH) and its splice variant hMena+11a: epidermal growth factor increases their expression and stimulates hMena+11a phosphorylation in breast cancer cell lines. Cancer Res 2007;67: 2657-65.
37. Bear JE, Loureiro JJ, Libova I, Fassler R, Wehland J, Gertler FB. Negative regulation of fibroblast motility by Ena/VASP proteins. Cell 2000;101:717-28.
38. Conti A, Ricchiuto P. lannaccone S, et al. Pigment epithelium-derived factor is differentially expressed in peripheral neuropathies. Proteomics 2005;5 4558-67.
39. Petty WJ, Dragnev KH, Memoli VA, et al. Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers Clin Cancer Res 2004;10:7547-54
40. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies J Clin Oncol 2001;19:3267-79
41. Janmaat ML, Kruyt FAE, Rodriguez JA. Giaccone G. Response to epidermal growth factor receptor inhibitors in non-small cell lung cancer cells limited antiproliferative effects and absence of apoptosis associated with persistent activity of extracellular signal-regulated kinase or Akt kinase pathways. Clin Cancer Res 2003;9:2316-26.
42. Saltz LB, Meropol NJ. Loehrer PJ, Sr.. Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8
43. Campiglio M, Locatelli A, Olgiati C, et al. Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (Iressa) is independent of EGFR expression level. J Cell Physiol 2004;198:259-68
44. Pino MS. Shrader M, Baker CH, et al. Transforming growth factor {α} expression drives constitutive epidermal growth factor receptor pathway activation and sensitivity to gefitinib (iressa) in human pancreatic cancer cell lines. Cancer Res 2006;66:3802-12
45. Katz M, Amit I. Citri A, et al. A reciprocal tensin-3- cten switch mediates EGF-driven mammary cell migration. Nat Cell Biol 2007;9:961-9
46. den Hartigh J, van Bergen en Henegouwen P Verkleij A, Boonstra J. The EGF receptor is an actin binding protein. J Cell Biol 1992;119:349-55
47. Jimeno A, Tan AC, Coffa J, et al. Coordinated epider mal growth factor receptor pathway gene overexpression predicts epidermal growth factor receptor inhibitor sensitivity in pancreatic cancer Cancer Res 2008;68:2841-9.
48. Yauch RL, Januario T, Eberhard DA, et al. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients. Clin Cancer Res 2005;11: 8686-98.
49. Herbst RS, Prager D, Hermann R., et al. TRIBUTE: a phase iii trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-9.
50. Perrais M, Chen X. Perez-Moreno M, Gumbiner BM E-cadherin homophilic ligation inhibits cell growth and epidermal growth factor receptor signaling indepen dently of other cell interactions. Mol Biol Cell 2007; 18:2013-25.